Table 1 Auxological and clinical characteristics of the patients by type of treatment.

From: Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty

Variable

GnRHa (n = 188)

GnRH + GH (n = 22)

P-value

CA (year)

8.20 ± 0.62

8.34 ± 0.44

0.298

BA (year)

10.30 ± 0.77

10.51 ± 0.61

0.198

BA (SDS)

3.59 ± 1.12

4.20 ± 1.21

0.020

BA–CA

2.10 ± 0.72

2.18 ± 0.73

0.634

Tanner stage (breast)

  

0.550

 II

130 (69.1%)

16 (72.7%)

 

 III

31 (58.5%)

88 (65.7%)

 

 IV

7 (2.1%)

0

 

Tanner stage (pubic hair)

  

0.552

 I

184 (97.9%)

22 (100.00%)

 

 II

4(2.1%)

  

Height

132.24 ± 5.17

128.52 ± 3.84

 < 0.001

Height SDS

1.10 ± 0.79

0.32 ± 0.73

 < 0.001

Weight (Kg)

30.94 ± 5.34

28.55 ± 4.00

0.043

Weight SDS

0.65 ± 3.25

0.37 ± 0.73

0.693

BMI (kg/m2)

17.64 ± 2.50

17.25 ± 1.73

0.479

BMI SDS

− 0.28 ± 10.63

0.29 ± 0.81

0.479

PAH (cm)

156.35 ± 6.34

150.41 ± 5.32

 < 0.001

PAH SDS

− 0.92 ± 1.31

− 2.17 ± 1.17

 < 0.001

TH (cm)

159.01 ± 3.69

158.93 ± 4.01

0.923

Basal LH (mIU/mL)

1.07 ± 0.86

1.15 ± 1.41

0.787

Basal FSH (mIU/mL)

2.50 ± 1.74

2.60 ± 1.29

0.796

Peak LH (mIU/mL)

11.89 ± 11.14

11.78 ± 9.57

0.964

Peak FSH (mIU/mL)

12.96 ± 4.39

13.46 ± 4.21

0.615

Duration of GnRHa treatment(year)

3.21 ± 0.73

3.00 ± 0.58

0.184

Time of menarche after GnRHa treatment (year)

1.34 ± 0.51

1.17 ± 0.53

0.145

Menarche age(year)

12.74 ± 0.60

12.50 ± 0.60

0.085

Duration of GH treatment after GnRHa treatment (months)

 

6.59 ± 7.77

 

Duration of total GH treatment (years)

 

2.99 ± 1.25

 
  1. GnRHa Gonadotropin-releasing hormone agonist, GH Growth hormone, CA Chronological age, BA Bone age, SDS Standard deviation score, BMI Body mass index, PAH Predicted adult height-calculated with advanced table of baley–Pinneau(BP)method, TH Target height, LH Luthenizing hormone, FSH Follicular stimulating hormone.
Back to article page